Not if you are under 60 or within ten years of your final period. That is the window where menopausal hormone therapy shows a favorable benefit-risk balance. In the Women's Health Initiative age-stratified analysis (Manson et al., JAMA 2013), women who started in their 50s had lower heart-disease risk than women who started in their 70s.
That single split is the reason the timing of the first dose matters as much as the dose itself. Here is what the evidence says about the window, where the ten-year line comes from and who it does not fit.
The Timing Hypothesis
The timing hypothesis holds that estrogen's effect on the arteries depends on the state of those arteries when treatment starts. Begin near menopause, when blood vessels are still relatively healthy, and estrogen looks neutral to protective for the heart. Begin many years later, after atherosclerosis has set in, and the same estrogen acts on plaque that is already there. Same drug, opposite direction, set by when you start.
This is why the 2002 WHI headline scared the wrong group. That trial used oral conjugated estrogen in women averaging 63 years old, well past menopause, and reported the pooled average. The absolute numbers were small in either direction: about 8 more breast cancers, 8 more strokes and 6 fewer colorectal cancers per 10,000 women per year on combined oral therapy. Applied to a 52-year-old with hot flashes, that average described a population she was not part of.
What the Trials Found
Two trials were built specifically to test timing, and both support the window.
| Factor | Start within 10 years / under 60 | Start 10+ years out / 60 and older |
|---|---|---|
| Coronary heart disease | Neutral to lower risk (ELITE, KEEPS) | Higher risk in the older WHI subgroup |
| Stroke | Small absolute increase | Larger absolute increase with age |
| Hot flash and sleep relief | Clear benefit | Clear benefit |
| Overall benefit-risk balance | Favorable | Less favorable, decided case by case |
ELITE, the Early versus Late Intervention Trial with Estradiol, gave estradiol to women who were either within six years of menopause or more than ten years out. The early group showed less progression of carotid artery thickening, while the late group saw no such benefit (Hodis et al., NEJM 2016). KEEPS, the Kronos Early Estrogen Prevention Study, studied women within three years of menopause and found a favorable symptom and safety profile over four years (Harman et al., 2014). Neither trial found the heart harm that the older WHI average implied for women who start early.
Where the Ten-Year Line Comes From
The ten-year figure is not a round number picked for convenience. The Menopause Society 2022 Hormone Therapy Position Statement (Menopause 2022;29(7):767-794) states that for healthy women under 60 or within ten years of menopause onset, the benefits of hormone therapy for hot flashes and bone protection outweigh the risks. In November 2025 the FDA removed the boxed warnings on cardiovascular disease and dementia from estradiol products and added label language supporting a start in exactly this group. The endometrial cancer warning on estrogen-alone products stayed in place, so a woman with a uterus still takes progesterone alongside estradiol to protect the lining.
When It Is Later Than the Window
The window is a starting point for the conversation, not a locked door. A first start at 60 or older, or more than ten years past menopause, has a less favorable balance, mostly because baseline cardiovascular risk climbs with age. It can still be reasonable for severe symptoms, but it calls for a closer look at heart and clot risk and a documented shared decision rather than an automatic yes. On Open Scripts a late or older start always routes to a video visit first and is never approved through the online flow alone.
Some histories change the answer regardless of age. A personal history of breast cancer, a blood clot, stroke or active liver disease weighs against systemic estrogen at any starting age. For those women a non-hormonal route can ease hot flashes without estrogen.
The Takeaway
If you are under 60 or within ten years of your last period and hot flashes, night sweats or broken sleep are wearing you down, the evidence is on the side of starting rather than waiting. The benefit-risk balance is most favorable early and narrows with each year past the window. The real question is less whether it is too late and more whether your age, symptoms and history fit the group the trials actually studied.
Reviewed By
Wondering whether your timing and history fit? Start an intake and a licensed clinician will review your age, symptoms and risk profile to see whether hormone therapy is appropriate.
This article is for education and is not a substitute for individual medical advice from your own clinician.